Curis (NASDAQ:CRIS – Get Free Report) will likely be announcing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($5.80) per share and revenue of $1.00 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET.
Curis (NASDAQ:CRIS – Get Free Report) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported ($25.00) EPS for the quarter, missing the consensus estimate of ($6.53) by ($18.47). On average, analysts expect Curis to post $-26 EPS for the current fiscal year and $-7 EPS for the next fiscal year.
Curis Stock Performance
Shares of CRIS opened at $4.72 on Tuesday. The firm has a market cap of $9.21 million, a P/E ratio of -0.20 and a beta of 3.08. Curis has a twelve month low of $3.61 and a twelve month high of $39.00. The firm’s 50 day moving average price is $7.59 and its two-hundred day moving average price is $13.11.
Wall Street Analysts Forecast Growth
View Our Latest Report on Curis
Hedge Funds Weigh In On Curis
A number of large investors have recently modified their holdings of the business. Squarepoint Ops LLC increased its position in shares of Curis by 17.9% in the third quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 8,973 shares during the last quarter. Jane Street Group LLC grew its stake in Curis by 71.8% in the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 10,586 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Curis during the 4th quarter worth approximately $26,000. Maverick Capital Ltd. increased its position in shares of Curis by 7.8% during the 2nd quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock worth $1,472,000 after purchasing an additional 49,554 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Curis by 37.3% during the 4th quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock worth $238,000 after purchasing an additional 65,404 shares in the last quarter. 29.97% of the stock is currently owned by institutional investors and hedge funds.
About Curis
Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.
Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.
Recommended Stories
- Five stocks we like better than Curis
- 5 AI Stocks Are Pulling Back—Which Growth Catalysts Still Look Strongest?
- Middleby Is Betting a Leaner Business Can Unlock More Value
- 3 Value ETFs to Consider as Growth Stocks Lag Behind
- Wintrust: A Quiet Regional Bank Posting Loud Results
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
